Why the study?
Does the efficacy of substrate-guided VT ablation differ between patients with ischaemic versus non-ischaemic dilated cardiomyopathy?
Does the efficacy of substrate-guided VT ablation differ between patients with ischaemic versus non-ischaemic dilated cardiomyopathy?
Substrate-guided VT ablation is less effective in patients with non-ischaemic dilated cardiomyopathy compared to those with ischaemic cardiomyopathy, with long-term outcomes strongly dependent on acute procedural success.
Answers are grounded in this paper and cite their sources.
May warrant etiology-specific ablation strategies in NIDCM; leaves open need for randomized validation before practice change.
AIMS: The purpose of this study was to evaluate the outcomes of purely substrate-guided ventricular tachycardia (VT) ablation in patients with non-ischaemic dilated cardiomyopathy (NIDCM) and ischaemic cardiomyopathy (ICM) and the impact of acute procedural success on long-term outcome. METHODS AND RESULTS: One hundred and forty-two patients (65 ± 12 years old, 72% male) with ICM (n = 87) and with NIDCM (n = 55) underwent substrate-guided VT ablation. The ablation approach involved eliminating all LP regions and ablating all scar border zone regions with 10 or more out of 12 pace-matching. All patients were followed with regular implantable defibrillator interrogations for mean 641 ± 301 days. Complete acute success (no inducible VT) was achieved in 60 patients with ICM (69%) and in 29 patients with NIDCM (53%) (P = 0.03). Partial success (elimination of clinical VT only) was obtained in nine patients with ICM (10%) and in four patients with NIDCM (7%) (P = 0.14). Procedural failure (clinical VT still inducible) occurred in 18 patients within the ICM group (21%) and in 22 patients of the NIDCM (40%) (P = 0.04). Overall, 51 patients presented with recurrence of ventricular arrhythmias: 23 in the group with ICM (26%) and 28 in the group with NIDCM (51%) (P = 0.03). Long-term success was related to acute procedural outcome. CONCLUSIONS: Substrate-guided ablation is an effective approach in the treatment of VT with long-term outcome directly related to acute procedural success. Success rates are significantly lower in patients with NIDCM compared with those with ICM.
No takes yet. Share an insight, caveat, or question.
Proietti et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: